SCLX Insider Trading

Insider Ownership Percentage: 8.73%
Insider Buying (Last 12 Months): $121,521.24
Insider Selling (Last 12 Months): $0.00

Scilex Insider Trading History Chart

This chart shows the insider buying and selling history at Scilex by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Scilex Share Price & Price History

Current Price: $2.15
Price Change: Price Increase of +0.54 (33.54%)
As of 06/17/2024 05:32 PM ET

This chart shows the closing price history over time for SCLX up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

Scilex Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/17/2024Jay ChunDirectorBuy57,500$0.90$51,750.00102,500View SEC Filing Icon  
5/16/2024Jaisim ShahInsiderBuy83,061$0.84$69,771.2498,943View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for Scilex (NASDAQ:SCLX)

69.67% of Scilex stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at SCLX by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Scilex Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
5/10/2024Vanguard Group Inc.3,988,265$6.34M0.0%+1.4%2.400%Search for SEC Filing on Google Icon
4/17/2024Cannon Global Investment Management LLC25,000$40K0.1%N/A0.015%Search for SEC Filing on Google Icon
4/9/2024Collective Family Office LLC21,950$35K0.0%+68.4%0.013%Search for SEC Filing on Google Icon
2/13/2024Tower Research Capital LLC TRC20,595$42K0.0%-82.7%0.013%Search for SEC Filing on Google Icon
2/12/2024Focus Financial Network Inc. ADV28,257$58K0.0%N/A0.018%Search for SEC Filing on Google Icon
2/6/2024Apollon Wealth Management LLC36,100$74K0.0%-27.8%0.023%Search for SEC Filing on Google Icon
1/19/2024Donald L. Hagan LLC52,343$0.11M0.1%+49.1%0.033%Search for SEC Filing on Google Icon
12/7/2023Hudson Bay Capital Management LP474,683$0.67M0.0%N/A0.301%Search for SEC Filing on Google Icon
10/24/2023Bank of New York Mellon Corp48,459$68K0.0%N/A0.032%Search for SEC Filing on Google Icon
10/11/2023Donald L. Hagan LLC35,098$49K0.0%+39.8%0.023%Search for SEC Filing on Google Icon
8/14/2023Casdin Capital LLC23,512$0.13M0.0%N/A0.016%Search for SEC Filing on Google Icon
8/11/2023Deuterium Capital Management LLC23,994$96K0.1%+25.8%0.016%Search for SEC Filing on Google Icon
8/10/2023Ground Swell Capital LLC12,085$67K0.2%N/A0.008%Search for SEC Filing on Google Icon
8/7/2023Wolverine Asset Management LLC8,224$46K0.0%N/A0.006%Search for SEC Filing on Google Icon
7/17/2023Donald L. Hagan LLC25,098$0.14M0.1%+66.2%0.017%Search for SEC Filing on Google Icon
7/17/2023GoalVest Advisory LLC7,279$41K0.0%N/A0.005%Search for SEC Filing on Google Icon
6/14/2023State Board of Administration of Florida Retirement System14,219$0.12M0.0%N/A0.010%Search for SEC Filing on Google Icon
5/11/2023Citigroup Inc.239,130$1.96M0.0%N/A0.164%Search for SEC Filing on Google Icon
5/11/2023E Fund Management Co. Ltd.31,431$0.26M0.0%N/A0.022%Search for SEC Filing on Google Icon
5/9/2023Tower Research Capital LLC TRC10,538$86K0.0%+1,159.0%0.007%Search for SEC Filing on Google Icon
5/9/2023California State Teachers Retirement System81,066$0.67M0.0%N/A0.056%Search for SEC Filing on Google Icon
5/9/2023US Bancorp DE4,512$37K0.0%N/A0.003%Search for SEC Filing on Google Icon
5/8/2023New York Life Investment Management LLC34,109$0.28M0.0%N/A0.023%Search for SEC Filing on Google Icon
5/8/2023Public Employees Retirement Association of Colorado4,709$39K0.0%N/A0.003%Search for SEC Filing on Google Icon
5/8/2023Zurcher Kantonalbank Zurich Cantonalbank8,554$70K0.0%N/A0.006%Search for SEC Filing on Google Icon
5/5/2023Mayo Clinic42,303$0.35M0.3%N/A0.029%Search for SEC Filing on Google Icon
5/2/2023Amalgamated Bank8,654$71K0.0%N/A0.006%Search for SEC Filing on Google Icon
4/28/2023Handelsbanken Fonder AB11,168$92K0.0%N/A0.008%Search for SEC Filing on Google Icon
4/27/2023Arizona State Retirement System17,904$0.15M0.0%N/A0.012%Search for SEC Filing on Google Icon
4/18/2023Donald L. Hagan LLC15,098$0.12M0.1%N/A0.010%Search for SEC Filing on Google Icon
4/18/2023ETF Managers Group LLC16,589$0.14M0.0%N/A0.011%Search for SEC Filing on Google Icon
4/14/2023Raymond James Financial Services Advisors Inc.18,409$0.15M0.0%N/A0.013%Search for SEC Filing on Google Icon
4/14/2023Raymond James & Associates31,303$0.26M0.0%N/A0.021%Search for SEC Filing on Google Icon
4/11/2023Asset Management Resources LLC19,459$0.16M0.1%N/A0.013%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Scilex logo
Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. The company is also developing three product candidates, including SP-102 (10 mg dexamethasone sodium phosphate viscous gel) (SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has completed a Phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4% (SP-103), a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a Phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules) (SP-104), a novel low-dose delayed-release naltrexone hydrochloride, which has completed Phase 1 trials for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California.
Read More on Scilex

Today's Range

Now: $2.15
Low: $1.67
High: $2.30

50 Day Range

MA: $1.06
Low: $0.75
High: $1.61

52 Week Range

Now: $2.15
Low: $0.73
High: $8.03

Volume

5,627,149 shs

Average Volume

995,807 shs

Market Capitalization

$389.56 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.01

Who are the company insiders with the largest holdings of Scilex?

Scilex's top insider investors include:
  1. Jay Chun (Director)
  2. Jaisim Shah (Insider)
Learn More about top insider investors at Scilex.

Who are the major institutional investors of Scilex?

Scilex's top institutional investors include:
  1. Vanguard Group Inc. — 2.40%
  2. Cannon Global Investment Management LLC — 0.02%
  3. Collective Family Office LLC — 0.01%
Learn More about top institutional investors of Scilex stock.

Which major investors are buying Scilex stock?

During the last quarter, SCLX stock was purchased by institutional investors including:
  1. Vanguard Group Inc.
  2. Cannon Global Investment Management LLC
  3. Collective Family Office LLC
During the previous year, these company insiders have bought Scilex stock:
  1. Jay Chun (Director)
  2. Jaisim Shah (Insider)
Learn More investors buying Scilex stock.